



Chiron Real Estate Inc. (XRN)

Updated April 15th, 2026, by Nikolaos Sismanis

Key Metrics

Current Price:	\$35	5 Year Annual Expected Total Return:	9.8%	Market Cap:	\$483 M
Fair Value Price:	\$34	5 Year Growth Estimate:	3.0%	Ex-Dividend Date:	04/20/26
% Fair Value:	103%	5 Year Valuation Multiple Estimate:	-0.5%	Dividend Payment Date:	05/15/26
Dividend Yield:	8.5%	5 Year Price Target	\$40	Years Of Dividend Growth:	0
Dividend Risk Score:	F	Sector:	Real Estate	Rating:	Sell

Overview & Current Events

Chiron Real Estate is a healthcare real estate company focused on owning net-lease healthcare facilities, off-campus outpatient medical buildings, and other specialized care properties leased to physician groups and regional or national health systems. Chiron operated for years as Global Medical REIT under the ticker GMRE, but in 2025 it completed a broader repositioning and corporate rebrand to Chiron Real Estate to reflect a wider strategic focus beyond its legacy GMRE identity. As of its latest filings, the portfolio comprised 189 properties totaling 5.1 million square feet and was 96% leased. The asset mix was weighted toward outpatient medical properties (72%), with additional exposure to inpatient rehabilitation facilities (16%) and other healthcare real estate (12%). Chiron trades at a market cap of \$483 million and pays dividends on a monthly basis.

On February 25th, 2026, Chiron Real Estate released Q4 and full-year results for the period ending December 31st, 2025. For the year, rental revenue increased to \$147.7 million from \$138.4 million in 2024, while total revenue rose to \$148.2 million from \$138.8 million. Adjusted Core FFO rose to \$65.8 million, or \$4.53 per share and unit, from \$63.4 million, or \$4.44 per share and unit, in 2024, while year-end leased occupancy was 96.0%. During the year, the company completed its rebrand to Chiron, amended and extended its credit facility, issued \$51.3 million of Series B preferred stock, and sold two facilities for \$11.3 million as part of its portfolio repositioning efforts. For 2026, we expect FFO per share of \$4.00.

Growth on a Per-Share Basis

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2031
AFFO	(\$0.15)	\$2.70	\$3.80	\$3.75	\$4.40	\$4.75	\$4.90	\$4.57	\$4.44	\$4.53	\$3.83	\$4.44
DPS	\$3.70	\$4.00	\$4.00	\$4.00	\$4.00	\$4.10	\$4.20	\$4.20	\$4.20	\$3.33	\$3.00	\$3.48
Shares¹	1.9	4.0	4.9	7.6	10.0	12.9	13.9	14.1	14.3	14.5	14.5	15.0

Most of the AFFO history here is really the old GMRE story. The weak results 2016 reflected an early-stage platform that was still building scale after its IPO, so AFFO was negative. From 2017 through 2018, AFFO rose sharply as GMRE added properties and began to include rent from acquisitions completed in prior periods.

As rental revenue kept rising in 2019, AFFO per share still slipped a bit because GMRE was expanding quickly and taking on higher fees, depreciation, amortization, and interest costs from acquisitions and the capital used to fund them. That started to reverse in 2020, then picked up in 2021–2022 as the company scaled, internalized management, kept buying medical properties, and generated more rent from a larger asset base. By 2021, GMRE had invested about \$196 million in medical real estate, helping lift AFFO per share, and 2022 marked the high point of that run.

From 2023 on, the story shifted to balance sheet pressure and portfolio cleanup. In 2023, GMRE used sale proceeds to cut leverage, which made strategic sense but held back near-term AFFO growth. In 2024, AFFO per share slipped again as higher borrowing costs, seven property sales, CEO transition costs, and a property impairment weighed on results. In 2025, under the Chiron Real Estate name, Core FFO improved modestly to \$4.53 per share, driven by same-property cash NOI growth, recent acquisitions, and portfolio repositioning.

¹ In millions



Chiron Real Estate Inc. (XRN)

Updated April 15th, 2026, by Nikolaos Sismanis

Moving forward, we forecast 3% growth to AFFO/share and the dividend, driven by lease escalators, stable occupancy, and selective capital recycling, supported by a balance sheet with no debt maturities until 2028.

Valuation Analysis

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	Now	2031
Avg. P/AFFO	---	16.7	11.2	14.6	14.4	15.7	12.7	10.5	10.3	7.9	9.2	9.0
Avg. Yld.	7.8%	8.9%	9.4%	7.3%	6.3%	5.5%	6.7%	8.8%	9.2%	9.2%	8.5%	8.7%

The valuation has compressed sharply from mid-teens P/AFFO levels to the high single digits lately, implying the market now views XRN as a slower-growth, higher-risk healthcare REIT. That de-rating makes sense in light of higher interest rates, limited AFFO growth, portfolio recycling, and weaker confidence after recent impairments and the GMRE-to-Chiron transition. Today, we believe the stock is more or less fairly valued. The dividend yield is lofty, adding to the appeal of the monthly dividend.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2031
Payout	---	148%	105%	107%	91%	86%	86%	92%	95%	74%	78%	78%

While Chiron boasts a 96%-leased healthcare portfolio and no debt maturities until 2028, these metrics mask a legacy of value destruction rooted in flawed capital allocation. The strategy under the former GMRE banner prioritized aggressive scale over asset quality, forcing the company into a cycle of "portfolio cleanup." This overextension led to \$3.2 million in impairments in 2024 and a 2025 net loss despite rising rental revenue as the cost of asset recycling, CEO turnover, and rebranding ate into shareholder equity. Ultimately, Chiron's history proves that high occupancy is no substitute for a competitive moat. Its "resilience" is undermined by need to constantly purge underperforming properties and manage tenant credit risks that should have been mitigated at acquisition. Still, we believe today's dividend is more sustainable.

Final Thoughts & Recommendation

Chiron is a high-yield monthly dividend healthcare REIT with some defensive appeal, but the upside depends on steady execution and moving past the legacy GMRE issues that hurt investor confidence. We see annualized returns of 9.8% through 2031, to be mainly driven by the dividend and projected growth. Chiron earns a sell rating due to the lack of progressive dividend growth, nonetheless.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Chiron Real Estate Inc. (XRN)

Updated April 15th, 2026, by Nikolaos Sismanis

Income Statement Metrics

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	8	30	53	71	94	110	137	157	156	161
Gross Profit	4	15	28	34	43	47	55	70	71	69
Gross Margin	53.6%	50.6%	52.2%	47.8%	45.4%	43.1%	40.2%	45.0%	45.8%	43.1%
SG&A Exp.	-	-	-	-	-	-	-	-	-	-
D&A Exp.	2	10	17	25	36	47	57	58	55	58
Operating Profit	(2)	7	22	27	16	31	38	54	50	49
Operating Margin	-27.0%	24.2%	41.1%	38.2%	17.3%	27.9%	27.9%	34.2%	32.1%	30.7%
Net Profit	(6)	(0)	15	10	(2)	18	20	22	7	(7)
Net Margin	-77.4%	-0.3%	27.4%	13.5%	-2.6%	16.7%	14.6%	13.9%	4.3%	-4.3%
Free Cash Flow	(153)	(240)	(159)	(220)	(184)	(133)	(80)	58	(25)	(8)
Income Tax	-	-	-	-	-	-	-	-	-	-

Balance Sheet Metrics

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	227	472	636	885	1,101	1,263	1,393	1,268	1,256	1,242
Cash & Equivalents	22	9	7	11	16	19	22	7	10	12
Accounts Receivable										
Inventories	-	-	-	-	-	-	-	-	-	-
Goodwill & Int. Ass.	7	-	-	-	6	6	6	6	6	6
Total Liabilities	72	213	336	425	643	626	744	662	701	712
Accounts Payable										
Long-Term Debt	67	202	317	389	595	584	705	624	658	672
Shareholder's Equity	155	171	194	355	370	548	558	509	2,296	386
LTD/E Ratio	0.43	0.82	1.18	0.90	1.34	0.94	1.11	1.07	1.23	1.32

Profitability & Per Share Metrics

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Assets	-4.3%	0.0%	2.6%	1.3%	-0.2%	1.6%	1.5%	1.6%	0.5%	-0.6%
Return on Equity	-8.2%	0.0%	5.2%	2.5%	-0.5%	3.3%	3.1%	3.5%	1.2%	-1.3%
ROIC	-4.4%	0.0%	2.7%	1.3%	-0.3%	1.6%	1.6%	1.7%	0.5%	-0.6%
Shares Out.	1.9	4.0	4.9	7.6	10.0	12.9	13.9	14.1	14.3	14.5
Revenue/Share	0.88	7.73	2.42	2.09	2.03	1.81	2.09	2.39	2.37	12.04
FCF/Share	(16.41)	(61.08)	(7.22)	(6.50)	(3.98)	(2.19)	(1.22)	0.89	(0.38)	(0.60)

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.